Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Share News (AVO)

  • There is currently no data for AVO

Advanced Oncotherapy Interim Loss Widens But LIGHT System Progresses

Mon, 30th Sep 2019 18:53

(Alliance News) - Cancer therapy developer Advanced Oncotherapy PLC on Monday reported a slightly widened half-year loss and said the final tranche of a fundraising effort has been increased by GBP400,000 due to investor demand.

In the six months to June 30, the company's pretax loss widened to GBP11.6 million from GBP11.5 million, with administrative expenses and finance costs rising.

Expenses increased by 2.6% year-on-year to GBP11.3 million from GBP11.0 million and finance costs totalled GBP588,638, up sharply from GBP173,239.

During the period, Advanced Oncotherapy conducted comparative studies of its Linac Image Guided Hadron Technology proton therapy treatment, which found that it is more cost effective and had "improved medical outcomes" than other proton therapy treatments.

In July, post-period end, the firm had announced that structural building work at the Harley Street refurbishment project in London was completed. Advanced Oncotherapy said the site is now ready for the "fit-out phase" which will see it move its LIGHT system to the building.

Advanced Oncotherapy said that due to increased demand, it issued 7.4 million new shares in the final phase of an equity fundraise. The stock will be priced at 40.00 pence each. This increases the last tranche of the financing to GBP2.9 million from GBP2.5 million, taking the total money raised to GBP18.8 million.

Shares in the company closed 6.1% higher at 42.44p each in London on Monday.

Executive Chair Michael Sinclair said: "We are delighted with the progress we have made over the first six months of 2019, on the technological as well as on the financial fronts.

"We believe the we have the necessary technology to deliver a system which offers more affordable, adaptive and precise proton therapy treatment. The LIGHT system is designed to have clear advantages over current proton therapy technologies in terms both of cost and clinical effectiveness. The additional funding we have received has contributed to de-risking the business model and provides a better position to pursue longer-term financing options."

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Related News

IN BRIEF: Advanced Oncotherapy financing talks continue, funds delayed
3 May 2024

IN BRIEF: Advanced Oncotherapy financing talks continue, funds delayed

Advanced Oncotherapy PLC - London-based provider of proton therapy for cancer treatment - Provides update in relation to financing discussions and fin...

TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec
2 Apr 2024

TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

EARNINGS AND TRADING: Frontier IP sells last of Exscientia holding
29 Feb 2024

EARNINGS AND TRADING: Frontier IP sells last of Exscientia holding

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

AVO.L News

IN BRIEF: Advanced Oncotherapy financing talks continue, funds delayed
3 May 2024

IN BRIEF: Advanced Oncotherapy financing talks continue, funds delayed

Advanced Oncotherapy PLC - London-based provider of proton therapy for cancer treatment - Provides update in relation to financing discussions and fin...

TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec
2 Apr 2024

TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

EARNINGS AND TRADING: Frontier IP sells last of Exscientia holding
29 Feb 2024

EARNINGS AND TRADING: Frontier IP sells last of Exscientia holding

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

IN BRIEF: Advanced Oncotherapy eyes USD15 million tranche in February
2 Feb 2024

IN BRIEF: Advanced Oncotherapy eyes USD15 million tranche in February

Advanced Oncotherapy PLC - London-based provider of proton therapy for cancer treatment - Regarding its recapitalisation plan, company works alongside...

IN BRIEF: Advanced Oncotherapy in advanced talks regarding loan
9 Jan 2024

IN BRIEF: Advanced Oncotherapy in advanced talks regarding loan

Advanced Oncotherapy PLC - London-based provider of proton therapy for cancer treatment - Continues to work on its recapitalisation plan with an unnam...

IN BRIEF: Advanced Oncotherapy in talks over possible cash injection
23 Oct 2023

IN BRIEF: Advanced Oncotherapy in talks over possible cash injection

Advanced Oncotherapy PLC - London-based provider of proton therapy for cancer treatment - Updates on financing discussions and current financial posit...

IN BRIEF: Advanced Oncotherapy results delayed, funding talks continue
3 Oct 2023

IN BRIEF: Advanced Oncotherapy results delayed, funding talks continue

Advanced Oncotherapy PLC - London-based provider of proton therapy for cancer treatment - On Friday, says it is not in a position to publish its accou...

Advanced Oncotherapy plans to raise up to GBP110 million
17 Jul 2023

Advanced Oncotherapy plans to raise up to GBP110 million

(Alliance News) - Advanced Oncotherapy PLC on Monday announced a prospective recapitalisation and funding plan to raise up to GBP110 million.